Anti-HLA-E Purified

*Nachmani D, Zimmermann A, Oiknine Djian E, Weisblum Y, Livneh Y, Khanh Le VT, Galun E, Horejsi V, Isakov O, Shomron N, Wolf DG, Hengel H, Mandelboim O: MicroRNA editing facilitates immune elimination of HCMV infected cells. PLoS Pathog. 2014 Feb 27;10 (2) :e1003963., URL: https://pubmed.ncbi.nlm.nih.gov/24586166/, *Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P: Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia. 2011 Sep;13 (9) :822-30., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=tremante+e+cerboni+c , *Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Horejsí V, Goldman-Wohl D, Yagel S, Mandelboim O: The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol. 2005 Oct 15;175 (8) :4866-74., URL: https://www.ncbi.nlm.nih.gov/pubmed/16210588?ordin, *Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP.: HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol. 2005 Jan;66 (1) :1-12., URL: https://www.ncbi.nlm.nih.gov/pubmed/15620456?dopt=, *Sibilio L. et al., Tissue Antigens 62, 339, 2003. (Abstract 45 from the 3rd Int. Conference on HLA-G, Paris, July 2003) ., URL: